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Abstract 
Objective: Biologically active cell penetrating peptides (CPPs) are an emerging class of therapeutic agent. The 
wasp venom peptide mastoparan is an established CPP that modulates mitochondrial activity and triggers caspase-
dependent apoptosis in cancer cells, as does the mastoparan analogue mitoparan (mitP). Mitochondrial depolarisa-
tion and activation of the caspase cascade also underpins the action of dithranol, a topical agent for treatment of pso-
riasis. The effects of a potent mitP analogue on mitochondrial activity were therefore examined to assess its potential 
as a novel approach for targeting mitochondria for the treatment of psoriasis.
Results: In HaCaT keratinocytes treated with the mitP analogue Z-Gly-RGD(DPhe)-mitP for 24 h, a dose-dependent 
loss of mitochondrial activity was observed using the methyl-thiazolyl-tetrazolium (MTT) assay. At 10 μmol L−1, MTT 
activity was less than 30% that observed in untreated cells. Staining with the cationic dye JC-1 suggested that Z-Gly-
RGD(DPhe)-mitP also dissipated the mitochondrial membrane potential, with a threefold increase in mitochondrial 
depolarisation levels. However, caspase activity appeared to be reduced by 24 h exposure to Z-Gly-RGD(DPhe)-mitP 
treatment. Furthermore, Z-Gly-RGD(DPhe)-mitP treatment had little effect on overall cell viability. Our findings suggest 
Z-Gly-RGD(DPhe)-mitP promotes the loss of mitochondrial activity but does not appear to evoke apoptosis in HaCaT 
keratinocytes.
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Introduction
Cell penetrating peptides (CPPs) have been studied 
extensively as vehicles that can traverse the plasma mem-
brane to mediate intracellular delivery of bioactive car-
goes including proteins, DNA and oligonucleotides [1, 2]. 
Most CPPs are inert molecules with cationic and hydro-
phobic residues that enable interactions with the cell sur-
face and subsequent direct penetration into the cell or 
uptake via endocytosis [3]. Biologically active molecules 
associated with the CPP are taken up at the same time, 
enabling them to reach their targets.
Recently, exploitation of the intrinsic biological activity 
of selected CPPs has emerged as a promising strategy for 
targeting intracellular events [4]. Such bioactive CPPs, 
designated bioportides, modulate a range of processes, 
including angiogenesis, apoptosis and MAP kinase sig-
nalling [5]. Mastoparan, a bioportide from wasp venom, 
promotes cell death in cancer cell lines [6, 7] as does 
mitoparan (mitP), a mastoparan analogue with enhanced 
cellular penetration properties [8]. Furthermore, mitP 
specifically co-localises with mitochondria in astrocy-
toma and bladder cancer cells, leading to depolarisation, 
permeabilisation of the inner mitochondrial membrane 
and apoptosis [8, 9].
The use of CPPs for cutaneous delivery of macromol-
ecules is emerging as a therapeutic approach for skin 
disorders [10]. However, the potential of bioportides 
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themselves to treat cutaneous disorders has received 
limited attention. Nonetheless, the ability of mitP to pro-
mote apoptosis in a mitochondria-dependent manner 
parallels the mode of action of dithranol, an established 
topical therapy for the inflammatory skin disorder pso-
riasis [8, 11, 12]. Interestingly, modification of mitP with 
Z-glycine, the integrin-specific motif RGD and a D iso-
mer of phenylalanine conferred enhanced potency on the 
peptide [8]. Therefore, in this study, we hypothesised that 
Z-Gly-RGD(DPhe)-mitP stimulates apoptosis in cultured 
keratinocytes. We found that Z-Gly-RGD(DPhe)-mitP 
treatment reduced mitochondrial activity and dissi-
pated the mitochondrial membrane potential in HaCaT 
keratinocytes but did not appear to trigger apoptosis.
Main text
Methods
The reagents and procedures for preparation of CPP 
Z-Gly-RGD(DPhe)-mitP were as described [8] and 
10 mmol L−1 stocks dissolved in water and stored − 20 °C 
until required. HaCaT keratinocytes were obtained and 
cultured as previously reported [13], seeded at 10,000/
well of 96-well plates, and exposed to the indicated con-
centrations of Z-Gly-RGD(DPhe)-mitP for 24  h. The 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) reagent was purchased from Sigma-
Aldrich (Gillingham, UK) and used in accordance with 
the manufacturer’s instructions, with absorbance meas-
urements at 570  nm. The sulphorhodamine SRB assay 
was performed as described [14] and absorbance deter-
mined at 492 nm. For mitochondrial depolarisation stud-
ies, cells were stained with 1 μmol L−1 of the fluorescent 
dye JC-1 for 75  min at 37  °C, harvested by trypsinisa-
tion and analysed on an Accuri C6 flow cytometer. The 
Caspase-Glo 3/7 assay (Promega, Southampton, UK) 
was used according to the manufacturer’s instructions to 
monitor apoptosis and luminescence captured on a Clari-
ostar plate reader (BMG Labtech, Aylesbury, UK).
Statistical analyses were performed in GraphPad 
Prism 5 (GraphPad Software, Inc., San Diego, CA) using 
unpaired t test with Welch’s correction which does not 
assume equal variances among the data.
Results
Z‑Gly‑RGD(DPhe)‑mitP alters mitochondrial activity
For initial assessment of the impact of Z-Gly-
RGD(DPhe)-mitP on HaCaT viability, mitochondrial 
activity was monitored using the MTT assay. Treat-
ment with Z-Gly-RGD(DPhe)-mitP for 24  h led to a 
dose-dependent reduction in mitochondrial activ-
ity (Fig.  1a). At 10  μmol  L−1, the CPP decreased MTT 
absorbance values to around 40% those of untreated cells. 
To determine whether loss of mitochondrial viability 
was associated with depolarisation mitochondria, JC-1 
staining was performed. Flow cytometry analyses 
revealed a dose-dependent elevation of mitochondrial 
depolarisation (Fig.  1b, c) following a 24  h exposure to 
Z-Gly-RGD(DPhe)-mitP, with threefold higher levels of 
depolarisation in cells treated with 10  μmol  L−1 of the 
CPP compared to untreated cells. Together, these results 
suggested that Z-Gly-RGD(DPhe)-mitP perturbed mito-
chondrial dynamics in HaCaT keratinocytes.
Effect of Z‑Gly‑RGD(DPhe)‑mitP on caspase activity
To evaluate the ability of Z-Gly-RGD(DPhe)-mitP to 
promote keratinocyte apoptosis, caspase 3/7 activity 
was monitored using a luciferase-based assay. Contrary 
to expectations, basal caspase activity appeared to be 
reduced by Z-Gly-RGD(DPhe)-mitP (Fig.  2a). Cell via-
bility was evaluated further using the SRB assay which 
monitors cell density based on the determination of cel-
lular protein content. As shown in Fig. 2b, CPP treatment 
had little effect on absorbance readings, suggesting cell 
density was largely unaffected by Z-Gly-RGD(DPhe)-
mitP. Thus the decline in mitochondrial activity (Fig.  1) 
or of caspase activity (Fig. 2a) does not appear to corre-
late with a general loss of cell viability as indicated by cel-
lular protein content.
Discussion
Despite recent progress in the provision of systemic 
therapy for severe psoriasis, topical anti-psoriasis regi-
mens for mild-to-moderate disease remain largely 
unsatisfactory [15]. Resistance to apoptosis has long 
been identified as a feature of psoriatic keratinocytes, 
and the induction of apoptosis appears to underpin the 
mechanism of action of dithranol, an established topi-
cal for treatment for psoriasis [11, 16]. By dissipating 
the mitochondrial membrane potential and promoting 
cytochrome c release, the CPPs mastoparan, mitP and 
Z-Gly-RGD(DPhe)-mitP stimulate apoptosis in tumour 
cells [8]. These observations prompted us to considered 
the effects of Z-Gly-RGD(DPhe)-mitP on keratinocytes 
given that dithranol exerts its effects on these cells at 
least in part via similar mitochondrial mechanisms [11]. 
Our findings suggest that Z-Gly-RGD(DPhe)-mitP depo-
larised keratinocyte mitochondria as expected. However, 
the loss of mitochondrial bioactivity was uncoupled from 
the induction of caspase-mediated apoptosis in HaCaT 
keratinocytes. Indeed, Z-Gly-RGD(DPhe)-mitP appeared 
to decrease HaCaT basal caspase activity under the con-
ditions used. Further studies are required in order to 
validate this putative anti-apoptotic effect of on Z-Gly-
RGD(DPhe)-mitP on keratinocytes to determine rele-
vance for skin disorders defined by extensive epidermal 
apoptosis, such as toxic epidermal necrolysis.
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Conclusions
The findings presented here indicate that Z-Gly-
RGD(DPhe)-mitP dissipates the mitochon-
drial membrane potential of HaCaT keratinocytes 
without apparently inducing cell death. Further modifi-
cation of Z-Gly-RGD(DPhe)-mitP or fusion to another 
peptide may thus be required for the development of a 
bioportide CPP as an alternative to dithranol.
Limitations
One major limitation of the study is that absence of com-
parative caspase 3/7 data with known inducers of apop-
tosis. The Fas ligand (FasL) is known to induce HaCaT 
keratinocyte apoptosis as determined by nucleosomal 
DNA fragmentation [17]. However, we observed lit-
tle effect on caspase 3/7 activity in HaCaT keratino-
cytes treated with FasL (data not shown). Therefore, 
additional measures of apoptosis, such as annexin V 
staining and DNA fragmentation are required. Further-
more, although the cell density SRB data do not suggest 
Fig. 1 Effect of Z-Gly-RGD(DPhe)-mitP on HaCaT keratinocyte 
mitochondrial activity. a Cells were treated with Z-Gly-RGD(DPhe)-
mitP for 24 h prior to evaluation of cell viability by MTT assay. b The 
proportions of cells depolarised after Z-Gly-RGD(DPhe)-mitP treat-
ment, assessed by JC-1 staining and normalised to untreated cells. 
Data were pooled from three independent experiments performed in 
duplicate. c Representative data showing increase of cell population 
with mitochondrial depolarisation (P11) indicated by JC-1 staining 
after 24 h treatment with the indicated concentrations of Z-Gly-
RGD(DPhe)-mitP. Data in shown in (a) and (b) are means + SEM; 
*p < 0.05, **p < 0.01, p < 0.0001; unpaired t test with Welch’s correc-
tion compared to the 0 μmol L−1 controls
Fig. 2 Alterations in caspase activity but not viability of HaCaT 
keratinocytes exposed to Z-Gly-RGD(DPhe)-mitP. Cells were treated 
with Z-Gly-RGD(DPhe)-mitP in serum-free medium for 24 h prior to 
(a) assessment of caspase 3/7 activity with a luminescence assay 
and (b) evaluation of cell density using the SRB assay. Data were 
pooled from three independent experiments performed in triplicate 
(a) or quadruplicate (b). Data shown are means + SEM; *p < 0.05; 
***p < 0.0001 unpaired t test with Welch’s correction compared to 
the 0 μmol L−1 controls
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Z-Gly-RGD(DPhe)-mitP promotes cell death, it will be 
important to confirm that the loss of HaCaT keratino-
cyte caspase activity associated Z-Gly-RGD(DPhe)-
mitP treatment is not due to necrosis. Finally, as the 
HaCaT keratinocyte cell line was used in this study, 
there remains a need to evaluate the impact of Z-Gly-
RGD(DPhe)-mitP on mitochondria and apoptosis in 
primary keratinocytes and 3D epidermal models of pso-
riasis, and use transcriptome-wide approaches to fully 
define the biological processes associated with the effects 
of Z-Gly-RGD(DPhe)-mitP in human keratinocytes.
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